- ISIN
- US31573L1052
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 31, 2024
Highlights
- Market Cap
- $1.47M
- Enterprise Value
- -$451.82K
- EPS (TTM)
- -$5.63
- Gross Profit (TTM)
- -$234.00K
- EBITDA (TTM)
- -$17.15M
- Year Range
- $0.62 - $13.00
- Target Price
- $180.00
- ROA (TTM)
- -228.77%
- ROE (TTM)
- -391.26%
- Avg. Volume (1M)
- 76K
- Avg. Volume Value (1M)
- $58.63K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
FBLG Performance Chart
FibroBiologics, Inc (FBLG) is down 84.4% since the beginning of the year. At $1 per share, FBLG is trading 94.6% below its 52-week high of $13.
Loading charts...
Compare this symbol against anything
Returns By Period
FibroBiologics, Inc (FBLG) has returned -84.44% so far this year and -94.60% over the past 12 months.
FibroBiologics, Inc
- 1D
- -2.67%
- 1M
- -20.05%
- 6M
- -89.45%
- YTD
- -84.44%
- 1Y
- -94.60%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -93.31%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
FBLG Monthly Returns History
Based on dividend-adjusted daily data since Jan 31, 2024, FBLG's average daily return is -0.64%, while the average monthly return is -13.05%.
Historically, 19% of months were positive and 81% were negative. The best month was Sep 2024 with a return of +90.7%, while the worst month was Mar 2026 at -79.9%. The longest winning streak lasted 1 consecutive months, and the longest losing streak was 6 months.
On a daily basis, FBLG closed higher 42% of trading days. The best single day was Feb 13, 2024 with a return of +88.4%, while the worst single day was Mar 31, 2026 at -42.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 47.53% | -0.96% | -79.91% | -0.00% | -12.12% | -18.30% | -26.14% | -84.44% | |||||
| 2025 | -19.50% | -21.74% | -28.57% | 24.44% | -34.87% | -14.71% | 2.38% | -7.36% | -7.44% | -27.99% | -30.33% | -17.92% | -88.76% |
| 2024 | -3.00% | -55.12% | -17.23% | -12.77% | 29.16% | -59.03% | 4.41% | -68.91% | 90.74% | -2.27% | -13.25% | -23.66% | -93.33% |
Benchmark Metrics
FibroBiologics, Inc has an annualized alpha of -81.35%, beta of 0.38, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since January 31, 2024.
- This stock participated in 434.42% of S&P 500 Index downside but only -171.09% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.38 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -81.35%
- Beta
- 0.38
- R²
- 0.00
- Upside Capture
- -171.09%
- Downside Capture
- 434.42%
Return for Risk
Risk / Return Rank
FBLG ranks 5 for risk / return — above 5% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for FibroBiologics, Inc (FBLG) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| FBLG | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.18 | ||
| Sortino ratioReturn per unit of downside risk | -4.07 | ||
| Omega ratioGain probability vs. loss probability | 0.72 | 1.25 | -0.53 |
| Calmar ratioReturn relative to maximum drawdown | -0.99 | 2.00 | -3.00 |
| Martin ratioReturn relative to average drawdown | -1.46 | 8.49 | -9.96 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the FibroBiologics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the FibroBiologics, Inc was 99.90%, occurring on Jul 27, 2026. The portfolio has not yet recovered.
The current FibroBiologics, Inc drawdown is 99.88%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.90%Jul 2026 | 2y 5mo | — | 2y 6moJan 2024 - now | — |
Drawdown Indicators
| FBLG | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.90% | -56.78% | -43.12% |
Max Drawdown (1Y)Largest decline over 1 year | -95.17% | -9.10% | -86.07% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.88% | -1.58% | -98.30% |
Average DrawdownAverage peak-to-trough decline | -90.95% | -10.70% | -80.25% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 64.43% | 2.14% | +62.29% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of FibroBiologics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how FibroBiologics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for FBLG in comparison with other companies in the Biotechnology industry. Currently, FBLG has a P/B value of 0.9. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with FBLG
Add FibroBiologics, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with FBLG